Holen Sie sich die Stockscreener-App
2.67
0.37%
-0.01
Handel nachbörslich:
2.72
0.05
+1.87%
Schlusskurs vom Vortag:
$2.68
Offen:
$2.66
24-Stunden-Volumen:
995.43K
Relative Volume:
1.83
Marktkapitalisierung:
$364.17M
Einnahmen:
$69.56M
Nettoeinkommen (Verlust:
$-240.05M
KGV:
-0.9051
EPS:
-2.95
Netto-Cashflow:
$-121.90M
1W Leistung:
-6.32%
1M Leistung:
-13.59%
6M Leistung:
+34.17%
1J Leistung:
-27.45%
1-Tages-Spanne:
$2.55
$2.7444
1-Wochen-Bereich:
$2.55
$2.95
52-Wochen-Spanne:
$1.05
$4.13
Adc Therapeutics Sa Stock (ADCT) Company Profile
Firmenname
Adc Therapeutics Sa
Sektor
Branche
Telefon
41 21 653 02 00
Adresse
BIOPOLE, EPALINGES
Vergleichen Sie ADCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
2.67 | 364.17M | 69.56M | -240.05M | -121.90M | -2.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-08 | Eingeleitet | Stephens | Overweight |
| 2024-05-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-03-28 | Eingeleitet | Guggenheim | Buy |
| 2023-08-10 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-04-24 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-12-06 | Eingeleitet | CapitalOne | Overweight |
| 2022-11-09 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-08-17 | Fortgesetzt | Jefferies | Buy |
| 2021-08-09 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-06-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-12-03 | Eingeleitet | Stifel | Hold |
| 2020-10-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-06-09 | Eingeleitet | BofA/Merrill | Buy |
| 2020-06-09 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Adc Therapeutics Sa Aktie (ADCT) Neueste Nachrichten
ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes - Quantisnow
Adc Therapeutics SA (NYSE: ADCT) Continues Its Downward Trend - Stocksregister
ADC Therapeutics Announces Updated ZYNLONTA Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma - marketscreener.com
ZYNLONTA shows 85% response rate in marginal zone lymphoma trial By Investing.com - Investing.com Nigeria
ZYNLONTA shows 85% response rate in marginal zone lymphoma trial - Investing.com Australia
Breakthrough Lymphoma Treatment: ZYNLONTA Shows 85% Response Rate with 27-Month Durability in Latest Trial - Stock Titan
Switzerland: ADC Therapeutics raises US$100m from PIPE financing - Investors in Healthcare
ADC Therapeutics (NYSE:ADCT) Stock Price Expected to Rise, Guggenheim Analyst Says - Defense World
Analysts Set Expectations for ADCT FY2026 Earnings - MarketBeat
Guggenheim Raises Price Target for ADC Therapeutics (ADCT) | ADCT Stock News - GuruFocus
ADC reports data from lymphoma trial, streamlines operations - MSN
ADC Therapeutics (ADCT) Price Target Raised Amid Strategic Moves - GuruFocus
ADC Therapeutics (ADCT) Secures $100M in PIPE Financing to Boost ZYNLONTA Development - GuruFocus
Layoff Tracker: ADC Therapeutics Cutting 30% of Staff, Closing London Research Facility - BioSpace
ADC Therapeutics (NYSE:ADCT) Price Target Raised to $10.00 at Guggenheim - MarketBeat
ADC Therapeutics price target raised to $10 from $7 on positive trial data By Investing.com - Investing.com South Africa
ADC Therapeutics announces $100M private financing - MSN
ADC Therapeutics price target raised to $10 from $7 on positive trial data - Investing.com India
ADC Therapeutics (ADCT) Price Target Raised Amid Strategic Moves | ADCT Stock News - GuruFocus
ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress - The Malaysian Reserve
ADC Therapeutics raises $100 million in private placement By Investing.com - Investing.com South Africa
ZYNLONTA-glofitamab combo shows 93.3% response rate in lymphoma trial By Investing.com - Investing.com South Africa
ADC Therapeutics Tightens Belt And Targets New Frontiers - Finimize
Transcript : ADC Therapeutics SASpecial Call - MarketScreener
ADC Therapeutics Announces $100M Private Placement - TipRanks
ADC Therapeutics to Cut 30% of Workforce, Shutter UK Site - MarketScreener
ADC Therapeutics : Corporate and Clinical Update June 2025 - MarketScreener
ADC Therapeutics (ADCT) Secures $100 Million in Private Equity F - GuruFocus
Adc Therapeutics Announces Updated Data from Lotis-7 Clinical Trial Presented At the European Hematology Association 2025 Congress - MarketScreener
ADC Therapeutics (ADCT) Secures $100 Million in Private Equity Financing | ADCT Stock News - GuruFocus
ADC Therapeutics raises $100 million in private placement - Investing.com Australia
ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028 - GuruFocus
Adc Therapeutics Announces $100 Mln Private Placement Extending Expected Cash Runway Into 2028 - marketscreener.com
ZYNLONTA-glofitamab combo shows 93.3% response rate in lymphoma trial - Investing.com
Wellington Management Group LLP Grows Stock Holdings in ADC Therapeutics SA (NYSE:ADCT) - MarketBeat
Equities Analysts Issue Forecasts for ADCT FY2026 Earnings - Defense World
Millennium Management LLC Sells 301,277 Shares of ADC Therapeutics SA (NYSE:ADCT) - MarketBeat
Two Sigma Investments LP Has $365,000 Stock Holdings in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Two Sigma Advisers LP Grows Stake in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Wellington Management Group LLP Purchases 84,785 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
Squarepoint Ops LLC Increases Position in ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics SA (NYSE:ADCT) Q1 2025 Earnings Call Transcript - MSN
Millennium Management LLC Decreases Stock Position in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Nuveen Asset Management LLC Purchases 22,989 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics Approves Key Proposals at Annual Meeting - TipRanks
ProShare Advisors LLC Increases Position in ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics SA (NYSE:ADCT) Shares Sold by Bank of America Corp DE - MarketBeat
ADC Therapeutics (ADCT) Shares Decline Amid Market Movement | AD - GuruFocus
Adc Therapeutics SA (NYSE: ADCT) Jumps 2.28%, Turning Investors Away - Stocksregister
ADC Therapeutics SA (NYSE:ADCT) Stock Position Boosted by Deutsche Bank AG - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Stock Position in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Finanzdaten der Adc Therapeutics Sa-Aktie (ADCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Adc Therapeutics Sa-Aktie (ADCT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Redmile Group, LLC | 10% Owner |
Dec 11 '24 |
Buy |
3.04 |
100,000 |
304,500 |
13,145,712 |
| Redmile Group, LLC | 10% Owner |
Dec 04 '24 |
Sale |
2.07 |
25,352 |
52,479 |
15,566,731 |
| Redmile Group, LLC | 10% Owner |
Jul 01 '24 |
Buy |
2.81 |
400,000 |
1,124,000 |
15,669,217 |
| Redmile Group, LLC | 10% Owner |
Jul 01 '24 |
Buy |
2.81 |
400,000 |
1,124,000 |
12,995,040 |
0.39%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):